Document is current
Any future updates will be listed below
-
Authors
Martínez, Carmen https://orcid.org/0000-0002-8401-7306
Khvedelidze, Irma
Fekom, Mathilde
Deau Fischer, Benedicte
Marouf, Amira
Ghesquières, Hervé
Fornecker, Luc-Mathieu
Merli, Francesco
Stefani, Piero Maria
Massaro, Fulvio
Botto, Barbara
Ferhanoğlu, Burhan
Akay, Olga Meltem
Özbalak, Murat https://orcid.org/0000-0002-3040-4052
Espeso de Haro, Manuel
Romero, Samuel
Galimard, Jaques-Emmanuel https://orcid.org/0000-0001-9102-4427
Glass, Bertram
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Sureda, Anna https://orcid.org/0000-0002-1238-6970
- License Information
-
More Information
Article History
Received: 28 November 2024
Revised: 24 February 2025
Accepted: 24 March 2025
First Online: 15 April 2025
Competing interests
: C. Martínez declares participation in Scientific Takeda Advisory Board. I. Khvedelidze declares no conflict of interest. M. Fekom declares no conflict of interest. B. Deau Fischer declares participation in Scientific Takeda and Abbvie Advisory board. A. Marouf declares no conflict of interest. H. Ghesquières declares Roche, BMS, Takeda consultancy; Honoraria: Gilead, Roche, BMS, Abbvie, Takeda. L.M. Fornecker declares no conflict of interest. F. Merli declares Honoraria/Advisory Board: Beigene, Gilead, Incyte, Janssen, Novartis, Roche, Sandoz, Takeda, Astrazeneca. P. M. Stefani declares participation in Advisory Board: Takeda, Roche, Janssen-Cilag, Incyte. Kiowa Kirin Gilead. F. Massaro declares no conflict of interest. B. Botto declares Takeda Speakers Bureau participation. B. Ferhanoğlu declares no conflict of interest. O. Meltem Akay declares no conflict of interest. M. Özbalak declares no conflict of interest. M. Espeso de Haro declares Research Funding: Pfizer; Advisory Board: Roche, Janssen, Abbvie, Kite, Takeda, Celgene. S. Romero declares no conflict of interest. J.E. Galimard declares no conflict of interest. B. Glass declares Roche, Consultancy, Membership on an entity’s Board ofDirectors or advisory committees, and Research Funding; Gilead, Consultancy and Membership on an entity’s Board ofDirectors or advisory committees; BMS, Consultancy and Membership on an entity’s Board ofDirectors or advisory committees; Miltenyi, Consultancy; Abbvie, Consultancy; Sobie, Consultancy; JAZZ, Honoraria. A. Bazarbachi declares Research support: Takeda, Novartis, Jansen, Roche and Pfizer; Honoraria: Takeda, Amgen, Caribou, Jansen, Roche. A. Sureda declares Takeda Honoraria, Membership on an entity’s Board of Directors or advisory committees and SpeakersBureau; Roche, Honoraria; Novartis, Honoraria and Membership on an entity’s Board ofDirectors or advisory committees; Janssen, Honoraria and Membership on an entity’s Board ofDirectors or advisory committees; BMS, Honoraria and Membership on an entity’s Board ofDirectors or advisory committees.
